Display options
Cite
Prieur G, Medrinal C, Combret Y, et al. Effect of high-flow nasal therapy during acute aerobic exercise in patients with chronic obstructive pulmonary disease after exacerbation: protocol for a randomised, controlled, cross-over trial. BMJ Open Respir Res. 2017;4(1):e000191doi: 10.1136/bmjresp-2017-000191.
Prieur, G., Medrinal, C., Combret, Y., Quesada, A. R., Prieur, F., Quieffin, J., Borel, J. C., & Reychler, G. (2017). Effect of high-flow nasal therapy during acute aerobic exercise in patients with chronic obstructive pulmonary disease after exacerbation: protocol for a randomised, controlled, cross-over trial. BMJ open respiratory research, 4(1), e000191. https://doi.org/10.1136/bmjresp-2017-000191
Prieur, Guillaume, et al. "Effect of high-flow nasal therapy during acute aerobic exercise in patients with chronic obstructive pulmonary disease after exacerbation: protocol for a randomised, controlled, cross-over trial." BMJ open respiratory research vol. 4,1 (2017): e000191. doi: https://doi.org/10.1136/bmjresp-2017-000191
Prieur G, Medrinal C, Combret Y, Quesada AR, Prieur F, Quieffin J, Borel JC, Reychler G. Effect of high-flow nasal therapy during acute aerobic exercise in patients with chronic obstructive pulmonary disease after exacerbation: protocol for a randomised, controlled, cross-over trial. BMJ Open Respir Res. 2017 Aug 16;4(1):e000191. doi: 10.1136/bmjresp-2017-000191. eCollection 2017. PMID: 29071072; PMCID: PMC5647475.
Copy Download .nbib Format: NLM
Share it on

BMJ Open Respir Res. 2017 Aug 16;4(1):e000191. doi: 10.1136/bmjresp-2017-000191. eCollection 2017.

Effect of high-flow nasal therapy during acute aerobic exercise in patients with chronic obstructive pulmonary disease after exacerbation: protocol for a randomised, controlled, cross-over trial.

BMJ open respiratory research

Guillaume Prieur, Clement Medrinal, Yann Combret, Aurora Robledo Quesada, Fabrice Prieur, Jean Quieffin, Jean Christian Borel, Gregory Reychler

Affiliations

  1. Pulmonology Department and Pulmonary Rehabilitation Department, Groupe Hospitalier du Havre, Montivilliers, France.
  2. Normandie UnivRouen France Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France.
  3. Pulmonology Department Groupe Hospitalier du Havre, Montivilliers, France.
  4. Physiotherapy Department, Groupe Hospitalier du Havre, Montivilliers, France.
  5. Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL & Dermatologie Université Catholique de Louvain, 1200 Brussels, Service de Pneumologie, Cliniques universitaires Saint-Luc, Brussels, Belgium.
  6. Pulmonology Department, Groupe Hospitalier du Havre, Montivilliers, France.
  7. Université Paris Saclay, Orsay Cedex, France.
  8. CIAMS Université d'Orléans, Orléans, France.
  9. Research and Development, Association AGIR à dom, Grenoble, France.
  10. Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL & Dermatologie, Université Catholique de Louvain, 1200 Brussels, Service de Pneumologie, Cliniques universitaires Saint-Luc, Brussels, Belgium.

PMID: 29071072 PMCID: PMC5647475 DOI: 10.1136/bmjresp-2017-000191

Abstract

INTRODUCTION: Early pulmonary rehabilitation is recommended after a severe exacerbation of chronic obstructive pulmonary disease (COPD). However, this is difficult to implement, particularly for exercise training. High-flow nasal therapy (HFNT) may reduce the work of breathing and dyspnoea and may improve exercise tolerance.

METHODS AND ANALYSIS: This is a single-centre, prospective, controlled, randomised, cross-over study. Eligible patients will have a diagnosis of COPD (postbronchodilator forced expiratory volume in 1 s/forced vital capacity ratio of <0.7). Two constant work rate exercise tests at 80% of the peak work rate will be carried out on two consecutive days with and without HFNT. The primary outcome will be the difference in endurance time between the two conditions. Secondary outcomes will be the change in muscle oxygenation during exercise, dyspnoea and muscle fatigue, respiratory muscle strength after exercise, respiratory rate, cardiac frequency, transcutaneous CO

ETHICS AND DISSEMINATION: Ethics approval has been obtained from the Ethics Committees Nord-Ouest III, Caen, France (N° ID RCB: 2016-A01325-46). The study will begin in April 2017 for a duration of 2 years. The results of the trial will be presented at national and international meetings and published in peer-reviewed journals.

TRIAL REGISTRATION NUMBER: NCT03058081.

Keywords: COPD; Exercise; High Flow Nasal Therapy; muscle oxygenation; pulmonary rehabilitation

Conflict of interest statement

Competing interests: None declared.

References

  1. Eur Respir J. 2015 Apr;45(4):879-905 - PubMed
  2. Thorax. 2002 Oct;57(10):847-52 - PubMed
  3. Eur Respir J. 2016 Feb;47(2):429-60 - PubMed
  4. Int J Chron Obstruct Pulmon Dis. 2016 May 25;11:1077-85 - PubMed
  5. Arch Phys Med Rehabil. 2008 Sep;89(9):1782-7 - PubMed
  6. Thorax. 2005 Nov;60(11):925-31 - PubMed
  7. Respir Med. 2014 Feb;108(2):319-28 - PubMed
  8. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7 - PubMed
  9. Eur Respir J. 2005 Jul;26(1):1-2 - PubMed
  10. Thorax. 2016 Aug;71(8):759-61 - PubMed
  11. Eur Respir J. 2004 May;23(5):698-702 - PubMed
  12. J Appl Physiol (1985). 2017 Jan 1;122(1):82-88 - PubMed
  13. Am J Respir Crit Care Med. 2002 Aug 15;166(4):518-624 - PubMed
  14. Chest. 1995 Jun;107(6):1590-7 - PubMed
  15. Chron Respir Dis. 2015 Feb;12(1):5-10 - PubMed
  16. Dtsch Arztebl Int. 2012 Apr;109(15):276-81 - PubMed
  17. Respir Med. 2016 Sep;118:128-132 - PubMed
  18. J Cardiopulm Rehabil Prev. 2015 Nov-Dec;35(6):431-8 - PubMed
  19. Crit Care Med. 2011 Jan;39(1):112-8 - PubMed
  20. COPD. 2005 Mar;2(1):105-10 - PubMed

Publication Types